Cargando…
The Effects on the Femoral Cortex of a 24 Month Treatment Compared to an 18 Month Treatment with Teriparatide: A Multi-Trial Retrospective Analysis
BACKGROUND: Teriparatide (TPTD) is an anabolic agent indicated for the treatment of severely osteoporotic patients who are at high risk of fragility fractures. The originally approved duration of TPTD treatment in several regions, including Europe, was 18 months. However, studies of areal bone miner...
Autores principales: | Whitmarsh, Tristan, Treece, Graham M., Gee, Andrew H., Poole, Kenneth E. S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747533/ https://www.ncbi.nlm.nih.gov/pubmed/26859142 http://dx.doi.org/10.1371/journal.pone.0147722 |
Ejemplares similares
-
An exploratory study into measuring the cortical bone thickness from CT in the presence of metal implants
por: Whitmarsh, Tristan, et al.
Publicado: (2017) -
Imaging the femoral cortex: Thickness, density and mass from clinical CT
por: Treece, G.M., et al.
Publicado: (2012) -
How does the femoral cortex depend on bone shape? A methodology for the joint analysis of surface texture and shape
por: Gee, A.H., et al.
Publicado: (2018) -
Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide
por: Blumsohn, A., et al.
Publicado: (2010) -
Can Three Months of Teriparatide Be One of Treatment Options for Osteoporotic Vertebral Compression Fracture Patients?
por: Kang, Jung Hoon, et al.
Publicado: (2019)